8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

______________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – May 24, 2005

_______________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

________________

Pennsylvania	1-8036		23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)		(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-2900

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On May 20, 2005, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that it would be hosting a conference call on Tuesday, May 24, 2005 at 9:00 am Eastern Time to further discuss the business and financial implications of the acquisition of The Tech Group, Inc. A copy of the press release is attached hereto as Exhibit 99.1. A copy of the conference call script and presentation slides are attached hereto as Exhibits 99.2 and 99.3, respectively.

The information in this report is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statement and Exhibits

(c)	Exhibits
	Exhibit #	Description
	99.1	West Pharmaceutical Services, Inc. Press Release, dated May 20, 2005.
	99.2	West Pharmaceutical Services, Inc. Conference call script.
	99.3	West Pharmaceutical Services, Inc. Conference call presentation slides.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ William J. Federici

William J. Federici

Vice President and Chief Financial Officer

May 24, 2005

Exhibit Index

Exhibit No.
99.1	West Pharmaceutical Services, Inc. Press Release, dated May 20, 2005.
99.2	West Pharmaceutical Services, Inc. Conference call script.
99.3	West Pharmaceutical Services, Inc. Conference call presentation slides.

EX-99

		Exhibit 99.1

West Pharmaceutical Services, Inc. Michael A. Anderson Vice President and Treasurer (610) 594-3345 mike.anderson@westpharma.com Media: Schwartz Communication Liza Heapes 781-684-0770 westpharma@schwartz-pr.com Investors and Financial Media: Financial Dynamics Julie Huang (212) 850-5628 wst@fd-us.com

West Pharmaceutical Services Completes Its Acquisition of The Tech Group

- Company will host conference call on Tuesday, May 24 at 9:00 am Eastern Time -

Lionville, PA, and Scottsdale, AZ May 20, 2005 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it has completed the acquisition of The Tech Group, Inc. on terms consistent with those described in the Companies’ earlier announcement of the transaction.

West will host a conference call to further discuss the business and financial implications of this acquisition on Tuesday, May 24, 2005 at 9:00 am Eastern Time. A live broadcast of the conference call will be available at the Company’s web site, http://www.westpharma.com/, in the “Investor” section. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the internet broadcast.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is the world's premier manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. West's customers include the world's leading pharmaceutical, biotechnology, generic drug and medical device producers. Headquartered in Lionville, Pennsylvania, West Pharmaceutical Services supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at http://www.westpharma.com

About The Tech Group

Founded in 1967 and based in Scottsdale, AZ, The Tech Group offers contract manufacturing solutions for the medical and consumer industries. Its customers include leaders in the healthcare, packaging and consumer/technology industries.

###

EX-99

West Pharmaceutical Services’
Acquisition of

The Tech Group

May 24, 2005

Safe Harbor Statement

Certain statements contained in this presentation and certain statements that may be made by management of the Company orally may contain forward-
looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate
strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate" and other words and terms of similar
meaning in connection with any discussion of future operating or financial performance or condition. In particular, these include statements concerning future
actions, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings
and financial results.

Because actual results are affected by risks and uncertainties, the Company cautions investors that actual results may differ materially from those
expressed or implied in any forward-looking statement.

It is not possible to predict or identify all such risks and uncertainties, but factors that could cause the actual results to differ materially from expected and
historical results include, but are not limited to: sales demand; the timing and commercial success of customers' products incorporating the Company’s
products and services; maintaining or improving production efficiencies and overhead absorption; competition from lower cost providers, particularly in the
European market; the Company's ability to develop and market value-added products; the average profitability, or mix, of products sold in a reporting period;
financial performance of unconsolidated affiliates; strength of the US dollar in relation to other currencies, particularly the Euro, UK pound, Danish Krone and
Singapore Dollar; inflation; US and international interest rates; returns on pension assets in relation to the expected returns employed in preparing the
Company's financial statements; raw material price escalation, particularly petroleum-based raw materials and energy costs; the resolution of Kinston-
related litigation and the adequacy of related insurance coverage; and the realization of the Company's investment in the clinical services operation upon
disposition.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised, however, to consult any further
disclosures the Company makes on related subjects in the Company's 10-K, 10-Q and 8-K reports.

In presenting this material or responding to inquiries in connection with a presentation, management may refer to results or performance measures that are
not prepared in accordance with US Generally Accepted Accounting Principles (“GAAP”) as reported in the Company’s recent 10Q and 8-K filings.  These
are Non-GAAP measures and are not intended to replace or as a substitute for results measured under GAAP, but rather as supplement to the GAAP
reported results.  Those 10-Q and 8-K filings include reconciliations of the GAAP and Non-GAAP results.

Transaction Overview

Definitive agreement announced April 29, 2005

Total Purchase price: $140 million

$20 million escrow for possible claims against reps and
warranties

$14 million escrow for performance milestones

Financed with available cash and new bank and private lender debt

West acquired The Tech Group’s nine production facilities in
Arizona, Michigan, Indiana, Puerto Rico, Mexico and Ireland, their
trade name and existing customer contracts

Closed on May 20, 2005

Deal expected to add $0.02 to $0.05 to WST 2005 EPS on $70MM
in revenue

Plastics Market Segments ‘04

Tech Group

West

$74.2M

$65.0MM

Evaluation Summary

Highly complementary

critical functions, culture, and management teams

Key platforms for future growth

Opportunity to expand consumer and assembled device
businesses

EU presence in pulmonary segment

Western US exposure to device OEM’s

Synergies come in two forms

Operational efficiencies

Potential to win new programs with combined technologies

Selected Major Customers

B. Braun

Baxter

Becton Dickinson

Ciba Vision

Gen-Probe

Gemplus

General Electric

Guidant

Hewlett Packard

Johnson & Johnson

Medtronic

Merck

Nektar Therapeutics

Ocular Science

Pall Medical

Proctor & Gamble

Sanford North America

Schering Plough

Wyeth